![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 24, 2024 11:12:48 AM
It's really hard to make any sort of evaluation of gameplan or timeframe on this one. I'll give you my *thoughts*, but that's all it is.
Denner is in a unique position where he has complete control of the board and the company. That is unusual, so it's not your typical "gameplan". Despite what some people have said over the past several months, I don't think Denner is going to "just dump it for 2 bucks". That is what people WANT so they can be done with this. But it has no basis in reality. If you look at the numbers, I can't think of any scenario where Vascepa is worth less than $5 a share. And even that is on the far low-end of reasonable ($5/share implies roughly $450-500M in PEAK revenues).
I think Denner needs a big win out of this one. His portfolio is sucking wind, and the majority of his holdings are in larger companies right now, so there's not a ton of upside there. But he has the opportunity to blow the doors off things with a big win with Amarin.
A reasonable starting point would be $10/share (IMO). That implies roughly $1B in PEAK worldwide revenues. I think that is very attainable for a BP. VERY attainable. But this does not really consider upside from anything beyond what we have in the U.S., plus China, EU and some little revenue in the RoW. If they find a way to re-capture the U.S. market, either through litigation or a new formulation, then all bets are off, and the number should go up from there.
But as it stands, I think $10-15 seems attainable. And I think the longer it takes, the stronger likelihood of a bigger number. If Denner thinks he can't get more than 5 bucks, he's not holding this thing for 3 more years. He's dumping it. But if he thinks he can get $10-15 (or more), then he can be patient and let those compound returns accumulate until the time is right.
I don't think anything will happen until there is more clarity on European approvals in Italy, France, and possibly Germany. They need to get those across the finish line. Amarin rolling out Vascepa on their own exposed the weakness across the globe, so now BP's that may have been champing at the bit in 2019 or far more reluctant to pursue Amarin until/unless they have assurances that they can actually get paid in the biggest countries they want to be in.
As far as litigation, I don't think they will wait for that. The litigation against Hikma could take 3 years, 5 years, 10 years. No way of knowing (unless there is something they already know). The GSK/Teva case has taken 10 years, and it's still not done. If we find a way to settle (favorably), in the next year or two, then that would be icing on the cake.
If I had to bet, I would say a sale happens late 2025 or into 2026. But that's also without knowing much of anything that is going on internally. I think the biggest clue that something is starting to happen will be when/if we see a flurry of activity (PR's, etc.) and rapid price growth. But while we still linger around a buck or less, nothing is happening.
Recent AMRN News
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM